Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.

Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.